MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Search

Prothena Corp PLC

Abierto

SectorSalud

10.35 2.17

Resumen

Variación precio

24h

Actual

Mínimo

10.08

Máximo

10.52

Métricas clave

By Trading Economics

Ingresos

-66M

-126M

Ventas

1.6M

4.4M

Margen de beneficio

-2,845.407

Empleados

163

EBITDA

14M

-52M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+27.83% upside

Dividendos

By Dow Jones

Próximas Ganancias

11 nov 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

161M

535M

Apertura anterior

8.18

Cierre anterior

10.35

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

183 / 371 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

Prothena Corp PLC Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

7 oct 2025, 16:58 UTC

Ganancias

BMW Trims 2025 View, Citing Weaker Performance in China

7 oct 2025, 23:43 UTC

Charlas de Mercado

Nikkei May Trade Rangebound; Takaichi's Policy Steps in Focus -- Market Talk

7 oct 2025, 23:36 UTC

Charlas de Mercado

Gold Edges Higher, Supported by Possible Hedging Demand -- Market Talk

7 oct 2025, 23:19 UTC

Charlas de Mercado

Veem Can Secure More Defense Deals Following Northrop Grumman Win -- Market Talk

7 oct 2025, 22:50 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

7 oct 2025, 22:50 UTC

Charlas de Mercado

RBNZ Should Take the Option of a Bigger Cut -- Market Talk

7 oct 2025, 22:40 UTC

Charlas de Mercado

South32's Alaskan Project Seen Starting Sooner, Worth More After U.S. Deal -- Market Talk

7 oct 2025, 21:56 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

7 oct 2025, 21:56 UTC

Charlas de Mercado

Australia Shares Set to Start Day Roughly Flat -- Market Talk

7 oct 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

7 oct 2025, 20:44 UTC

Acciones populares

Stocks to Watch Tuesday Recap: Oracle, Dell, Trilogy Metals -- WSJ

7 oct 2025, 19:42 UTC

Charlas de Mercado

Treasury Yields Fall as Data Blackout Continues -- Market Talk

7 oct 2025, 19:23 UTC

Adquisiciones, fusiones, absorciones

Private-Equity Stocks Have Gotten Crushed. J.P. Morgan Says This One Is a Buy. -- Barrons.com

7 oct 2025, 19:07 UTC

Charlas de Mercado

Oil Futures Settle Mixed With Higher OPEC+ Supply in View -- Market Talk

7 oct 2025, 19:02 UTC

Charlas de Mercado

U.S. Natural Gas Posts Back-to-Back Gains -- Market Talk

7 oct 2025, 16:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

7 oct 2025, 16:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

7 oct 2025, 16:20 UTC

Charlas de Mercado

Home Depot Extended Pro Desk Hours Could Drive Sales Growth -- Market Talk

7 oct 2025, 16:15 UTC

Charlas de Mercado

AMD's OpenAI Deal Resets Competitive Landscape for Chips -- Market Talk

7 oct 2025, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

7 oct 2025, 15:37 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

7 oct 2025, 15:37 UTC

Charlas de Mercado

Markets for Canadian Aluminum Open Up Beyond U.S. -- Market Talk

7 oct 2025, 15:33 UTC

Charlas de Mercado

Gold Rise Tied to Lower Confidence in Dollar Assets -- Market Talk

7 oct 2025, 15:25 UTC

Charlas de Mercado

Canadian Mining Stocks Rally on U.S. Defense Dept. Deal -- Market Talk

7 oct 2025, 15:15 UTC

Charlas de Mercado

Investors Look to Gold, Bitcoin as Traditional Correlations Break Down -- Market Talk

7 oct 2025, 15:04 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

7 oct 2025, 15:04 UTC

Charlas de Mercado

Canadian Aluminum Exports Squeezed by Tariffs -- Market Talk

7 oct 2025, 14:56 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

7 oct 2025, 14:56 UTC

Charlas de Mercado

U.S. Government Shutdown May Impact Release of Canadian Trade Data -- Market Talk

7 oct 2025, 14:52 UTC

Ganancias

These Stocks Are Moving the Most Today: Tesla, AMD, Ford, Dell, IBM, AppLovin, Trilogy Metals, Aehr, and More -- Barrons.com

Comparación entre iguales

Cambio de precio

Prothena Corp PLC Esperado

Precio Objetivo

By TipRanks

27.83% repunte

Estimación a 12 meses

Media 13 USD  27.83%

Máximo 20 USD

Mínimo 4 USD

De acuerdo con 6 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Prothena Corp PLC Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

6 ratings

4

Comprar

1

Mantener

1

Vender

Puntuación técnica

By Trading Central

N/A / 7.35Soporte y Resistencia

Corto Plazo

Strong Bearish Evidence

Medio plazo

Very Strong Bearish Evidence

Largo Plazo

Weak Bearish Evidence

Sentimiento

By Acuity

183 / 371 Clasificación en Salud

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Prothena Corp PLC

Prothena Corporation PLC is a late-stage clinical company. The Company is engaged in the protein dysregulation and a pipeline of therapeutics for devastating neurodegenerative and rare peripheral amyloid diseases. It is advancing a pipeline of therapeutic candidates around neurological dysfunction and the biology of misfolded proteins. The Company's clinical pipeline of antibody-based product candidates targets a range of indications, including Birtamimab for the treatment of amyloid light-chain (AL) amyloidosis; prasinezumab for the treatment of Parkinson’s disease and other related synucleinopathies; and PRX004, for the treatment of Transthyretin amyloidosis (ATTR). The Company's pipeline also includes late-preclinical-stage programs targeting proteins implicated in neurological diseases including tau and amyloid beta (Aß) for the treatment of Alzheimer’s disease and other neurodegenerative disorders, and TDP-43 for the treatment of amyotrophic lateral sclerosis.
help-icon Live chat